Medication Study for those with Relapsing Remitting Multiple Sclerosis (Ages 18-65)
Official Title
A Phase 3 Open Label Study to Evaluate the Long-term Safety and Tolerability of ALKS 8700 in Adults with Relapsing Remitting Multiple Sclerosis
Purpose
The purpose of this study is to evaluate the long-term safety and tolerability of a drug (ALKS 8700) used to treat adults with Relapsing Remitting Multiple Sclerosis.
Could this study be right for you?
You may be eligible for this study if you:
- are between 18 and 65 years of age
- have a confirmed diagnosis of Relapsing Remitting Multiple Sclerosis
- EDSS score of 0.0-6.0 at screening and visit 2